Berthold DR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5. Abstract

Crook JM et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367(10):895-903. Abstract

De Bono JS et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. Proc ASCO 2012;Abstract 4519.

De Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376(9747):1147-54. Abstract

Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983-92. Abstract

Halperin EC, Perez CA, Brady LW, eds. Principles and Practice of Radiation Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

Harrison MR et al. Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013;5:1-14. Abstract

Hussain M et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368(14):1314-25. Abstract

Kantoff P et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium 2010;Abstract 8.

Kantoff PW et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22. Abstract

McDevitt MR et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25(9):1341-51. Abstract

Parker C et al. Updated survival, quality of life (QOL), and safety data of radium-223 chloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). Proc ESMO 2012. No abstract available

Porter AT et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Biol Phys 1993;25(5):805-13. Abstract

Ryan CJ et al. Interim analysis results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Proc ASCO 2012;Abstract LBA4518.

Sartor O. Androgen deprivation — Continuous, intermittent, or none at all? N Engl J Med 2012;367(10):945-6. Abstract

Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97. Abstract

Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract